{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:09:49Z","timestamp":1790690989030,"version":"4.1.0"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.hoc.2026.08.006","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:52:18Z","timestamp":1790689938000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitors"],"prefix":"10.1016","author":[{"given":"Manlin","family":"Shao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Huntoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5618","key":"10.1016\/j.hoc.2026.08.006_bib1","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1126\/science.1083653","article-title":"Assembly of cell regulatory systems through protein interaction domains","volume":"300","author":"Pawson","year":"2003","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.hoc.2026.08.006_bib2","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"issue":"7216","key":"10.1016\/j.hoc.2026.08.006_bib3","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nature07385","article-title":"Comprehensive genomic characterization defines human glioblastoma genes and core pathways","volume":"455","year":"2008","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.hoc.2026.08.006_bib4","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2026.08.006_bib5","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.hoc.2026.08.006_bib6","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","article-title":"Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions","volume":"22","author":"Wen","year":"2020","journal-title":"Neuro Oncol"},{"issue":"21","key":"10.1016\/j.hoc.2026.08.006_bib7","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1111\/febs.12393","article-title":"The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered","volume":"280","author":"Gan","year":"2013","journal-title":"FEBS J"},{"issue":"8","key":"10.1016\/j.hoc.2026.08.006_bib8","article-title":"Anti-epidermal growth factor receptor therapy for glioblastoma in adults. Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group","volume":"2020","author":"Lee","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.hoc.2026.08.006_bib9","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2026.08.006_bib10","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/neuonc\/noac173","article-title":"Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial","volume":"25","author":"Lassman","year":"2023","journal-title":"Neuro Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2026.08.006_bib11","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1158\/2159-8290.CD-11-0284","article-title":"Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors","volume":"2","author":"Vivanco","year":"2012","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.hoc.2026.08.006_bib12","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1093\/neuonc\/noab133","article-title":"Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma","volume":"23","author":"Marin","year":"2021","journal-title":"Neuro Oncol"},{"issue":"6166","key":"10.1016\/j.hoc.2026.08.006_bib13","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1126\/science.1241328","article-title":"Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA","volume":"343","author":"Nathanson","year":"2014","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.hoc.2026.08.006_bib14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"8","key":"10.1016\/j.hoc.2026.08.006_bib15","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1158\/2159-8290.CD-13-0879","article-title":"EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing","volume":"4","author":"Francis","year":"2014","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.hoc.2026.08.006_bib16","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41588-018-0105-0","article-title":"Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma","volume":"50","author":"deCarvalho","year":"2018","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.hoc.2026.08.006_bib17","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","article-title":"An integrative model of cellular States, plasticity, and genetics for glioblastoma","volume":"178","author":"Neftel","year":"2019","journal-title":"Cell"},{"issue":"16","key":"10.1016\/j.hoc.2026.08.006_bib18","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1101\/gad.1890510","article-title":"Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma","volume":"24","author":"Inda","year":"2010","journal-title":"Genes Dev"},{"issue":"19","key":"10.1016\/j.hoc.2026.08.006_bib19","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1056\/NEJMoa051918","article-title":"Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors","volume":"353","author":"Mellinghoff","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.006_bib20","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1200\/JCO.2004.08.110","article-title":"Phase II trial of gefitinib in recurrent glioblastoma","volume":"22","author":"Rich","year":"2004","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2026.08.006_bib21","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1227\/neu.0000000000003383","article-title":"Congress of neurological surgeons systematic review and evidence-based guidelines update for the role of emerging therapies in the management of patients with metastatic brain tumors","volume":"96","author":"Huntoon","year":"2025","journal-title":"Neurosurgery"},{"issue":"8","key":"10.1016\/j.hoc.2026.08.006_bib22","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1200\/JCO.2008.17.5984","article-title":"Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034","volume":"27","author":"van den Bent","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.006_bib23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/imm.70102","article-title":"Stem cell-based delivery of immunomodulators for overcoming glioblastoma immune evasion","volume":"178","author":"T-Ardah","year":"2026","journal-title":"Immunology"},{"issue":"7","key":"10.1016\/j.hoc.2026.08.006_bib24","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1158\/1078-0432.CCR-18-1140","article-title":"Rindopepimut with bevacizumab for patients with relapsed EGFRvIII-Expressing glioblastoma (ReACT): results of a double-blind randomized phase II trial","volume":"26","author":"Reardon","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.hoc.2026.08.006_bib25","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1093\/neuonc\/nox105","article-title":"Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification","volume":"19","author":"Sep\u00falveda-S\u00e1nchez","year":"2017","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2026.08.006_bib26","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s11060-021-03834-3","article-title":"Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutation","volume":"154","author":"Cardona","year":"2021","journal-title":"J Neuro Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2026.08.006_bib27","doi-asserted-by":"crossref","DOI":"10.2217\/cns-2019-0014","article-title":"Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma","volume":"8","author":"Makhlin","year":"2019","journal-title":"CNS Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.006_bib28","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1158\/1078-0432.CCR-19-1871","article-title":"Preclinical comparison of the blood-brain barrier permeability of osimertinib with other EGFR TKIs","volume":"27","author":"Colclough","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.hoc.2026.08.006_bib29","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf146","article-title":"Resistance of recurrent epidermal growth factor receptor-altered glioblastoma to anti-epidermal growth factor receptor targeted therapy with osimertinib","volume":"30","author":"Villanacci","year":"2025","journal-title":"Oncologist"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2026.08.006_bib30","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.16_suppl.TPS2098","article-title":"Randomized phase 2 study to evaluate the efficacy and safety of silevertinib in combination with temozolomide in newly diagnosed patients with EGFRvIII-positive IDHwt MGMT unmethylated glioblastoma","volume":"44","author":"Wen","year":"2026","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2026.08.006_bib31","first-page":"2068","article-title":"Phase 1 study of BDTX-1535, an oral 4th generation covalent EGFR inhibitor, in patients with recurrent glioblastoma: preliminary dose escalation results","volume":"42","author":"Wen","year":"2024","journal-title":"J Clin Orthod"},{"issue":"4","key":"10.1016\/j.hoc.2026.08.006_bib32","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ejca.2014.12.019","article-title":"A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma","volume":"51","author":"Westphal","year":"2015","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.hoc.2026.08.006_bib33","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1093\/annonc\/mdp032","article-title":"Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma","volume":"20","author":"Neyns","year":"2009","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.006_bib34","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s10143-025-03335-1","article-title":"Are EGFR monoclonal antibodies associated with clinical benefits in patients with glioma: a systematic review, meta-analysis, and specific analysis on glioblastoma and diffuse intrinsic pontine glioma","volume":"48","author":"Habibi","year":"2025","journal-title":"Neurosurg Rev"},{"issue":"6","key":"10.1016\/j.hoc.2026.08.006_bib35","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1093\/neuonc\/nox202","article-title":"Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma","volume":"20","author":"Gan","year":"2018","journal-title":"Neuro Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2026.08.006_bib36","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1158\/1535-7163.MCT-17-0710","article-title":"Characterization of ABBV-221, a tumor-selective EGFR-targeting antibody drug conjugate","volume":"17","author":"Phillips","year":"2018","journal-title":"Mol Cancer Ther"},{"issue":"15","key":"10.1016\/j.hoc.2026.08.006_bib37","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1158\/1078-0432.CCR-24-0426","article-title":"Bystander effects, pharmacokinetics, and linker-payload stability of EGFR-targeting antibody-drug conjugates losatuxizumab vedotin and Depatux-M in glioblastoma models","volume":"30","author":"Jain","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.006_bib38","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1124\/jpet.110.167601","article-title":"Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux","volume":"334","author":"Agarwal","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.hoc.2026.08.006_bib39","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1124\/dmd.118.084210","article-title":"Brain distribution of a panel of epidermal growth factor receptor inhibitors using cassette dosing in wild-type and Abcb1\/Abcg2-Deficient mice","volume":"47","author":"Kim","year":"2019","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.006_bib40","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/S1470-2045(17)30689-7","article-title":"Leptomeningeal metastases in non-small-cell lung cancer","volume":"19","author":"Cheng","year":"2018","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2026.08.006_bib41","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1021\/acsmedchemlett.9b00599","article-title":"Development of a potent brain-penetrant EGFR tyrosine kinase inhibitor against malignant brain tumors","volume":"11","author":"Tsang","year":"2020","journal-title":"ACS Med Chem Lett"},{"issue":"368","key":"10.1016\/j.hoc.2026.08.006_bib42","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag0976","article-title":"AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases","volume":"8","author":"Yang","year":"2016","journal-title":"Sci Transl Med"},{"issue":"7","key":"10.1016\/j.hoc.2026.08.006_bib43","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S1474-4422(10)70105-8","article-title":"Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers","volume":"9","author":"Jansen","year":"2010","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.hoc.2026.08.006_bib44","first-page":"166","article-title":"Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma","volume":"60","author":"Van Meir","year":"2010","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.hoc.2026.08.006_bib45","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.ijrobp.2012.10.008","article-title":"Rtog 0211: a phase 1\/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients","volume":"85","author":"Chakravarti","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"34","key":"10.1016\/j.hoc.2026.08.006_bib46","doi-asserted-by":"crossref","first-page":"5603","DOI":"10.1200\/JCO.2008.18.0612","article-title":"Phase I\/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177","volume":"26","author":"Brown","year":"2008","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2026.08.006_bib47","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2008.18.9639","article-title":"Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma","volume":"27","author":"Prados","year":"2009","journal-title":"J Clin Oncol"},{"issue":"36","key":"10.1016\/j.hoc.2026.08.006_bib48","doi-asserted-by":"crossref","first-page":"5524","DOI":"10.1200\/JCO.23.00493","article-title":"Inaugural results of the individualized screening trial of innovative glioblastoma therapy: a phase II platform trial for newly diagnosed glioblastoma using bayesian adaptive randomization","volume":"41","author":"Rahman","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.006_bib49","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/neuonc\/noy091","article-title":"Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial","volume":"21","author":"Lassman","year":"2019","journal-title":"Neuro Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2026.08.006_bib50","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.ijrobp.2026.04.013","article-title":"Mechanisms, microenvironments, and models: understanding therapeutic resistance in glioblastoma","volume":"125","author":"Wisdom","year":"2026","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hoc.2026.08.006_bib51","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.drup.2019.04.002","article-title":"The TICking clock of EGFR therapy resistance in glioblastoma: target Independence or target compensation","volume":"43","author":"Saleem","year":"2019","journal-title":"Drug Resist Updat"},{"issue":"6","key":"10.1016\/j.hoc.2026.08.006_bib52","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1158\/1535-7163.MCT-19-0609","article-title":"Depatuxizumab mafodotin (ABT-414)-induced glioblastoma cell death requires EGFR overexpression, but not EGFRY1068 phosphorylation","volume":"19","author":"von Achenbach","year":"2020","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.006_bib53","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/cam4.4939","article-title":"Distribution and favorable prognostic implication of genomic EGFR alterations in IDH -wildtype glioblastoma","volume":"12","author":"Higa","year":"2023","journal-title":"Cancer Med"},{"issue":"6","key":"10.1016\/j.hoc.2026.08.006_bib54","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1158\/0008-5472.CAN-20-1810","article-title":"Therapy-induced transdifferentiation promotes glioma growth independent of EGFR signaling","volume":"81","author":"Oh","year":"2021","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.hoc.2026.08.006_bib55","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/nn.4584","article-title":"A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma","volume":"20","author":"Guo","year":"2017","journal-title":"Nat Neurosci"},{"issue":"2","key":"10.1016\/j.hoc.2026.08.006_bib56","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00280-009-1041-6","article-title":"A phase I\/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation","volume":"65","author":"Thiessen","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"10.1016\/j.hoc.2026.08.006_bib57","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/neuonc\/noz222","article-title":"INTELLANCE 2\/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma","volume":"22","author":"Van Den Bent","year":"2020","journal-title":"Neuro Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2026.08.006_bib58","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/neuonc\/nov013","article-title":"Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas","volume":"17","author":"van den Bent","year":"2015","journal-title":"Neuro Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2026.08.006_bib59","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1016\/j.celrep.2020.02.014","article-title":"Glioblastoma cell resistance to EGFR and MET inhibition can be overcome via blockade of FGFR-SPRY2 bypass signaling","volume":"30","author":"Day","year":"2020","journal-title":"Cell Rep"},{"issue":"15","key":"10.1016\/j.hoc.2026.08.006_bib60","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1038\/s41388-021-01721-9","article-title":"EGFRvIII tumorigenicity requires PDGFRA co-signaling and reveals therapeutic vulnerabilities in glioblastoma","volume":"40","author":"Yeo","year":"2021","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.hoc.2026.08.006_bib61","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1158\/1078-0432.CCR-15-1677","article-title":"InsR\/IGF1R pathway mediates resistance to EGFR inhibitors in glioblastoma","volume":"22","author":"Ma","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"5848","key":"10.1016\/j.hoc.2026.08.006_bib62","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1126\/science.1142946","article-title":"Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies","volume":"318","author":"Stommel","year":"2007","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.hoc.2026.08.006_bib63","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1158\/0008-5472.CAN-14-2004","article-title":"A urokinase receptor-bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma","volume":"75","author":"Wykosky","year":"2015","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.hoc.2026.08.006_bib64","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1073\/pnas.96.8.4240","article-title":"New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase\/AKT pathway","volume":"96","author":"Cantley","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"35","key":"10.1016\/j.hoc.2026.08.006_bib65","doi-asserted-by":"crossref","first-page":"14164","DOI":"10.1073\/pnas.1211962109","article-title":"Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240","volume":"109","author":"Fenton","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.006_bib66","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1186\/s12967-025-07216-5","article-title":"Glioblastoma resistance to EGFR antibody-drug conjugate is driven by transcriptional reprogramming and TEK-induced EGFR suppression","volume":"23","author":"Blomquist","year":"2025","journal-title":"J Transl Med"},{"key":"10.1016\/j.hoc.2026.08.006_bib67","article-title":"A phase 0\/1 study of BDTX-1535 in recurrent high-grade glioma (rHGG) and newly diagnosed glioblastoma (nGBM) participants with EGFR alterations or fusions","year":"2023","journal-title":"ClinicalTrials.gov"},{"issue":"857","key":"10.1016\/j.hoc.2026.08.006_bib68","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adx8398","article-title":"EGFR inhibition down-regulates MGMT and enhances responsiveness to temozolomide in glioblastoma","volume":"18","author":"Nayab","year":"2026","journal-title":"Sci Transl Med"},{"issue":"10","key":"10.1016\/j.hoc.2026.08.006_bib69","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.hoc.2026.08.006_bib70","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1200\/JCO-25-01137","article-title":"Evaluation of regorafenib in newly diagnosed and recurrent glioblastoma: GBM AGILE phase II\/III bayesian randomized platform trial","volume":"44","author":"Wen","year":"2026","journal-title":"J Clin Oncol"},{"issue":"7741","key":"10.1016\/j.hoc.2026.08.006_bib71","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41586-019-0882-3","article-title":"Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid","volume":"565","author":"Miller","year":"2019","journal-title":"Nature"},{"issue":"399","key":"10.1016\/j.hoc.2026.08.006_bib72","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O\u2019Rourke","year":"2017","journal-title":"Sci Transl Med"},{"issue":"9","key":"10.1016\/j.hoc.2026.08.006_bib73","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat Biotechnol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826001073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826001073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:52:27Z","timestamp":1790689947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858826001073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":73,"alternative-id":["S0889858826001073"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2026.08.006","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2026.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}